• Streptavidin-HyperFluor 647 in Modern Proteomics

  2026-10-05

  Streptavidin-HyperFluor™ 647 is a fluorescent streptavidin reagent designed for visualizing biotinylated targets, while a 2026 study describes a different, biotin-free BmTyr proximity-labeling strategy in primary T cells. This overview compares the two evidence bases, explains where a streptavidin fluorescent conjugate may fit conceptually in proteomic and imaging research, and identifies important limits concerning assay specificity, spectral performance, biological interpretation, and the lack of direct validation of this product in the cited study.

• ACE2, Diminazene Aceturate, and Sepsis Cardiomyopathy

  2026-10-05

  A February 2024 study examined whether pharmacological ACE2 activation protects the septic heart through MasR-Sirt1 signaling and mitochondrial biogenesis. In a mouse sepsis model, DIZE was associated with improved cardiac function and reduced inflammatory, oxidative, and apoptotic injury, while ACE2 inhibition produced the opposite pattern; however, the findings remain preclinical and pharmacologically dependent.

• Antipyrine in Translational BBB Research

  2026-10-04

  A source-grounded perspective on Antipyrine as a comparator for BBB modeling, CNS pharmacokinetics, and translational research strategy.

• Acetylcholine Chloride and Gut–Brain Signaling

  2026-10-03

  Acetylcholine Chloride is a research-use chemical relevant to studies of cholinergic neurotransmission, but the supplied evidence does not show that this product was used in the reported Bacteroides fragilis epilepsy study. Jia et al. describe a gut–vagus–brain mechanism in which B. fragilis is associated with activation of colonic ChAT-positive cells, enhanced vagal cholinergic signaling, and seizure suppression in mouse models, with a reported randomized clinical trial in pediatric refractory epilepsy. This overview separates those findings from broader interpretation, compares evidence strength, and defines major translational limitations.

• CB-839 (Telaglenastat) in MYCN Metabolism

  2026-10-02

  PRMT5 inhibition has revealed a compelling connection between RNA splicing, epitranscriptomic regulation, and glutamine metabolism in MYCN-amplified neuroblastoma. This article explains how CB-839 (Telaglenastat) can serve as a direct, selective GLS1 probe to test whether impaired glutaminolysis is a causal vulnerability, while outlining biomarker, combination, handling, and translational strategies for cancer metabolism research.

• GPNMB Model Predicts ESCC Immunotherapy Response

  2026-10-01

  This study identifies circulating soluble GPNMB as a mechanistically linked marker of CD8+ T-cell exhaustion and resistance to PD-1 blockade in esophageal squamous cell carcinoma. By integrating plasma GPNMB, CAF-Epi niche features, and clinicopathological variables, the authors develop a multimodal framework for predicting treatment response and survival.

• Rhamnolipid mRNA Nanovaccines Target Dendritic Cells

  2026-10-01

  This Advanced Functional Materials study replaces PEG-lipids with microbial rhamnolipids to create stabilized, self-adjuvanting mRNA lipid nanoparticles. The resulting formulation improved dendritic-cell targeting, lymph-node expression, adaptive immune responses, and repeat-dose tolerability in the reported experimental systems.

• DiscoveryProbe Metabolism-related Compound Library

  2026-09-30

  The DiscoveryProbe Metabolism-related Compound Library enables mechanism-guided metabolic screening informed by clinical metabolomics. This article translates burn-associated hypermetabolism findings into a practical, multimodal assay strategy for enzyme, lipid, stress, and cancer metabolism research.

• Angiotensin I/II (1-5) Protocol and QC Guide

  2026-09-30

  Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for controlled renin-angiotensin system research involving blood pressure regulation and aldosterone signaling. This guide covers solvent selection, storage, vehicle controls, and QC while setting clear limits: no product-specific dose-response or efficacy claims are made, and use outside cardiovascular or renal workflows requires model-specific validation.

• FK866 (APO866): Translating NAMPT Dependency in AML

  2026-09-29

  FK866 (APO866) offers translational researchers a precise way to interrogate NAMPT dependency, NAD depletion, mitochondrial stress, and caspase-independent cell death in acute myeloid leukemia. This article connects mechanistic biology with assay strategy, biomarker development, formulation practice, and a carefully bounded comparison with PARP inhibitor resistance research.

• GPNMB Model Predicts ESCC Immunotherapy Response

  2026-09-29

  This study identifies circulating soluble GPNMB as a mechanistically linked biomarker of resistance to PD-1 blockade in esophageal squamous cell carcinoma. By combining plasma GPNMB, CAF-Epi niche features, and clinicopathological variables, the authors develop a multimodal framework intended to improve response prediction and patient stratification.

• Phenacetin B1453 for Reliable Cell Assays

  2026-09-28

  Learn how Phenacetin (SKU B1453) can support controlled exposure, viability, and pharmacokinetic workflows when solvent compatibility, compound identity, and data interpretation are critical. This scenario-based guide connects product specifications with human pluripotent stem cell-derived intestinal organoid research while clearly separating evidence from practical recommendations.

• PDK4-IN-1 Hydrochloride: From Target to Flux

  2026-09-28

  PDK4-IN-1 hydrochloride is a selective pyruvate dehydrogenase kinase 4 inhibitor for probing PDH regulation and mitochondrial metabolism. This article focuses on how to connect target inhibition to metabolic flux—and avoid mistaking downstream changes for proof of PDK4 engagement.

• Deuterated Degarelix: A 13-Step Synthesis

  2026-09-27

  This study reports a route to deuterium-labeled degarelix acetate, using D₂O/D₃PO₄ to prepare a deuterated naphthyl amino-acid building block for peptide assembly. The 13-step synthesis delivered the labeled target in 14% overall yield, providing a candidate analytical standard for studies that require isotopically labeled degarelix.

• HHV-7 DNA in Ocular Toxoplasmosis: Case Findings

  2026-09-26

  A 2023 case report detected both Toxoplasma gondii and human herpesvirus 7 (HHV-7) DNA in vitreous fluid from a patient with recurrent, treatment-refractory ocular toxoplasmosis. The findings raise the possibility that HHV-7 reactivation contributed to inflammation, while also showing why molecular detection in a single patient cannot establish causality.

7980 records 1/532 page Next 12345 下5页 Last page